Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Cancer

Volumn 118, Issue 7, 2012, Pages 1827-1837

  Shanafelt, Tait D ^a   Kay, Neil E ^a   Rabe, Kari G ^a   Inwards, David J ^a   Zent, Clive S ^a   Leis, Jose F ^a   Schwager, Susan M ^a   Thompson, Carrie A ^a   Bowen, Deborah A ^a   Witzig, Thomas E ^a   Slager, Susan L ^a   Call, Timothy G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic lymphocytic lymphoma (CLL); Physician expertise; Prognosis; Small lymphocytic lymphoma (SLL)

Indexed keywords

ALKYLATING AGENT; ANTIBODY; PURINE NUCLEOSIDE; STEROID;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HEMATOLOGIST; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL SPECIALIST; ONCOLOGIST; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; SEX; SURVIVAL TIME; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL COMPETENCE; DATABASES AS TOPIC; FEMALE; HEMATOLOGY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS;

EID: 84858708449     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26474     Document Type: Article

References (43)

1. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327-2340. (Pubitemid 30350226)
2. Davis S, Dahlberg S, Myers MH, Chen A, Steinhorn SC. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst. 1987;78: 471-478. (Pubitemid 17036761)
3. Feuer EJ, Frey CM, Brawley OW, et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol. 1994;12:368-377.
4. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet. 1993;341:999-1002. (Pubitemid 23109178)
5. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst. 1999;91:839-846.
6. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991;9:818-826.
7. Horowitz MM, Przepiorka D, Champlin RE, et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood. 1992;79:2771-2774.
8. Ayanian JZ, Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat. 1996;40:65-74. (Pubitemid 26283491)
9. Adams JL, Mehrotra A, Thomas JW, McGlynn EA. Physician cost profiling - reliability and risk of misclassification. N Engl J Med.362:1014-1021.
10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood. 2008;111: 5446-5456.
11. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
12. Gribben JG. How I treat CLL upfront. Blood. 2010;115: 187-197.
13. Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program. 2007;2007:324-331.
14. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
15. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-523.
16. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378-4384.
17. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single- agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28: 1749-1755.
18. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow- up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912-4920.
19. Keating M, O'brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
20. Hallek M. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood. 2008;112:Abstract #325.
21. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405-411. (Pubitemid 46105933)
22. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376:1164-1174.
23. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141:615-621. (Pubitemid 351667621)
24. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007:332-338.
25. Loberiza FR Jr, Cannon AJ, Weisenburger DD, et al. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol. 2009;27:5376-582.
26. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group Guidelines fo Chronic Lymphocytic Leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997. (Pubitemid 26189840)
27. Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia (CLL) from monoclonal B-cell lymphocytosis (MBL) based on clinical outcome. Blood. 2009;113:4188-4196.
28. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115:363-372.
29. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116:4777-4787.
30. Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139:398-404. (Pubitemid 47512176)
31. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49: 49-56. (Pubitemid 351146882)
32. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone- rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48:2412-2417. (Pubitemid 350253473)
33. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008;141:607-614. (Pubitemid 351667615)
34. Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008;140:537-546. (Pubitemid 351230080)
35. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorscence in hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol. 2003;121:287-295. (Pubitemid 36560596)
36. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861. (Pubitemid 34042903)
37. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634-4641. (Pubitemid 46630962)
38. Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007;25:4648-4656. (Pubitemid 350041550)
39. Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
40. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438. (Pubitemid 26161205)
41. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
42. Rai K, Peterson BL, Appelbaum FR, et al. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood. 2009;114:Abstract 536.
43. Shanafelt TD, Gunderson H, Call TG. Commentary: chronic lymphocytic leukemia-the price of progress. Oncologist. 2010;15:601-602.